Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Sophie Vallet 1, * Sylvie Larrat 2 Syria Laperche 3 Hélène Le Guillou-Guillemette 4 Florence Legrand-Abravanel Françoise Bouchardeau 3 Adeline Pivert Cécile Henquell Audrey Mirand Elisabeth André-Garnier Valérie Giordanengo 5 Gisèle Lagathu 6 Vincent Thibault 7 Caroline Scholtes Evelyne Schvoerer 8 Catherine Gaudy-Graffin 9 Sarah Maylin Pascale Trimoulet 10 Etienne Brochot 11, 12 Sébastien Hantz 13 Joël Gozlan 14 Anne-Marie Roque-Afonso 15 Patrick Soussan 16 Jean-Christophe Plantier 17 Charlotte Charpentier 18 Stéphane Chevaliez 3, 19 Philippe Colson 20 Vincent Mackiewicz Lina Aguilera Sylvain Rosec 21 Stéphanie Gouriou 1 Nelly Magnat Françoise Lunel-Fabiani 4 Jacques Izopet 22 Patrice Morand 2 Christopher Payan 1 Jean-Michel Pawlotsky 3, 19
Abstract : Hepatitis C virus (HCV) protease inhibitor resistance-associated substitutions are selected during triple-therapy breakthrough. This multicenter quality control study evaluated the expertise of 23 French laboratories in HCV protease inhibitor resistance genotyping. A panel of 12 well-defined blinded samples comprising two wild-type HCV strains, nine transcripts from synthetic NS3 mutant samples or from clinical strains, and one HCV RNA-negative sample was provided to the participating laboratories. The results showed that any laboratory with expertise in sequencing techniques should be able to provide reliable HCV protease inhibitor resistance genotyping. Only a 0.7% error rate was reported for the amino acid sites studied. The accuracy of substitution identification ranged from 75% to 100%, depending on the laboratory. Incorrect results were mainly related to the methodology used. The results could be improved by changing the primers and modifying the process in order to avoid cross-contamination. This study underlines the value of quality control programs for viral resistance genotyping, which is required prior to launching observational collaborative multicenter studies on HCV resistance to direct-acting antiviral agents.
Type de document :
Article dans une revue
Journal of Clinical Microbiology, American Society for Microbiology, 2013, 51 (5), pp.1428-33. 〈10.1128/JCM.03032-12〉
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-00935958
Contributeur : Ghislaine Calvez <>
Soumis le : vendredi 24 janvier 2014 - 11:44:36
Dernière modification le : jeudi 18 janvier 2018 - 02:13:42

Identifiants

Citation

Sophie Vallet, Sylvie Larrat, Syria Laperche, Hélène Le Guillou-Guillemette, Florence Legrand-Abravanel, et al.. Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.. Journal of Clinical Microbiology, American Society for Microbiology, 2013, 51 (5), pp.1428-33. 〈10.1128/JCM.03032-12〉. 〈hal-00935958〉

Partager

Métriques

Consultations de la notice

664